ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

NCT01903330 ↗

Phase 2 Unknown 84 enrolled Epitopoietic Research Corporation University of California, Irvine · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

This phase II clinical trial studies how well ERC1671 plus Granulocyte-macrophage colony-stimulating factor (GM-CSF) plus Cyclophosphamide with Bevacizumab works compared to Placebo Injection plus Placebo Pill with Bevacizumab in treating patients with recurrent/progressive, bevacizumab naïve glioblastoma multiforme and gliosarcoma (World Health Organization (WHO) grade IV malignant gliomas, GBM).

Timeline

Start: 2014-03
Primary completion: 2026-03
Completion: 2026-06

Publications

Schijns VE, Pretto C, Devillers L, Pierre D, Hofman FM, Chen TC, Mespouille P, Hantos P, Glorieux P, Bota DA, Stathopoulos A. First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity. Vaccine. 2015 May 28;33(23):2690-6. doi: 10.1016/j.vaccine.2015.03.095. Epub 2015 Apr 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cyclophosphamide	Other / unclassified	50 mg	Oral
Subject	ERC1671	Vaccine	—	Other
Subject	GM-CSF	Protein / enzyme biologic	500 ug	Other
Background	Bevacizumab	Monoclonal antibody	10 mg/kg	Intravenous

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

Summary

Timeline

Publications

Drugs

Indications